JWHolding

2024

- Commenced Export of Comprehensive Nutritional Infusion 'Winuf' to Mongolia
- Registered Korean Patent for Wnt-targeted Hair Loss Treatment ‘JW0061’
- Signed License-In Agreement with Kissei Pharmaceutical for GnRH Antagonist ‘Linzagolix’
- C&C Research Laboratories, Prostate cancer treatment selected as Korea Drug Development Project

2023

- Completion of relocation to new headquarters in Gwacheon, strengthening 'R&D-focused' management system
- Wnt-targeted hair loss treatment 'JW0061' selected for National New Drug Development Project
- Acquisition of international standard compliance management system 'ISO 37301' certification
- Korean patent registration for sepsis early diagnosis biomarker specific binding antibody
- Launch of Korea's first 'Hybrid Incubator'

2022

- Selection of STAT3-targeted anti-cancer drug 'JW2286' for National New Drug Development Project
- Joint research agreement with Ilias BioLogics
- Joint research agreement with Organoid Science for preclinical translational research
- Joint research agreement with OncoCross for innovative new drug using AI

2021

- Completion of a phase 2b clinical trial of the anti-gout drug URC102
- Enter a phase 2b dose-ranging clinical trial of the new atopic dermatitis drug candidate JW1601
- Signed a non-cxclusive license agreement with Immunovia(Sweden) for the patent 'diagnostic biomarker of pancreatic cancer'
- World's 1st Europeon&Chinese patent registration of diagnostic technique for sepsis
- Signed a license agreement for Fostamatinib with Kissei Pharmaceutical Co.,Ltd.
- The cumulative output of IV product exceed 3 billion

2020

- Obtainment of a US patent for an early diagnosis technology of pancreatic cancer
- Joint development of a next-generation nutrient sap with Baxter
- Conclusion of the Winuf® exclusive technology exportation and provision agreement with Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. in China

2019

- C&C Research Laboratories, JW Pharmaceutical Subsidiary transfer
- Signed a technology export contract with the Simcere company in China, 'URC102' for gout treatment
- Acquired 'Euvipharm', the first Vietnamese pharmaceutical company in Korea
- Atopic dermatitis ‘JW1601’ won the ‘Technology Exporter’ and the 'King Sejong the Great', the highest patented technology in Korea
- Acquired patents for China and Europe for early diagnosis of pancreatic cancer
- A hemophilia drug 'hemri Bra' rare drug designation and market sales permit
- Asia’s first sell a three-chamber nutrient infusion in EU

2018

J- W Life Science Industry First "Nutrient Toolking" in Asia Get EU – GMP
- Technology export of atopic dermatitis drug 'JW1601'

2017

- 2017 Signed export contract for ‘Ertapenem’, the next generation antibiotic with Gland Pharma from India

2016

- JW Lifescience listed on Securities Market

2015

- Vision 70+5 Declaration

2013

- Signed Export Agreement with America’s Baxter for - 3-Chamber Nourishment Transfusion Fluid Joint-Development - agreement with Japan’s SKK worth 100 billion for - pharmaceutical products Founded True Medical Personnel - respecting life, enacted ‘Sungcheon Award’

2012

- CRelocation of C&C new medicine research institute - (DRC hall, Sungkyunkwan University, Suwon natural science campus)

2011

- Renamed to JW Holdings Corporation
- Renamed to JW Pharmaceutical Corporation
- Renamed to JW Shinyak Corporation
- Renamed to JW Life Science Corporation
- Renamed to JW Medical Corporation
- Renamed to JW Living Healthcare Corporation

2010

- JW Dangjin Production Complex, which is Korea’s largest
- Medicine-manufacturing plant, was built

2009

- JW Shinyak was listed on the KOSDAQ Awarded
- US$30 mil-Export Tower

2008

- Took over Three-Seven Certified as Good Labor Culture Enterprise from Labor Ministry Eco-friendly B1 established

2007

- Awarded Presidential Citation on the occasion of Environment
- Day Choongwae Holdings established

2006

- World’s largest Non-PVC supplement plant (Dangjin) was built

2005

- Designated as Korea’s 30-respectable enterprises(Dong-A Ilbo Daily, IBM BCS)
- Designated as Asia’s 200 outstanding enterprises (Fobes Asia)
- Choongwae Shinyak established

2004

- Antibiotics, ‘Impenem’ first generic with US$600 mil-scale - potential Global market developed Impenem plant meeting - EU GMP standard was built (Sihwa)

2003

- Awarded the 3rd Gyeonggi Green Environment Trophy  - (Gyeonggi Province)
- Awarded the 4th Korea Business Image Grand Prize by KMAC
- Awarded the 5th Industrial Peace Grand Prize

2002

- Awarded New Medicine Development Prize with Balofloxacin (Ginko biloba leaf extract)
- Antibiotics Ketoconnazole was certified by Europe COS